Women’s Metabolic Health & PMOS
Women’s metabolic health is shaped by a dynamic interaction between hormonal, reproductive, metabolic and cardiovascular factors. Conditions such as PMOS, gestational diabetes, obesity, thyroid dysfunction and menopause-associated metabolic change need a life-stage-specific approach.
Different life stages, different metabolic needs.
PMOS (polyendocrine metabolic ovarian syndrome) is one of the most common endocrine-metabolic disorders in women of reproductive age. It is strongly linked to insulin resistance, obesity, Type 2 diabetes, dyslipidaemia and long-term cardiovascular risk, as well as fertility and mental-health concerns.
Pregnancy is a metabolic stress test. Gestational diabetes and hypertensive disorders of pregnancy not only affect mother and baby but also signal a substantially higher lifetime risk of diabetes and cardiovascular disease — making postpartum follow-up an important prevention opportunity.
Menopause brings changes in body composition, lipids, insulin sensitivity and bone density. IMACH recognises the importance of integrating women’s health into the broader framework of metabolic medicine, bringing together endocrinologists, gynaecologists, obstetricians, diabetologists, nutritionists and primary care professionals.
Key areas of scientific focus
PMOS & reproduction
- PMOS and metabolic dysfunction
- Insulin resistance and reproductive health
- Obesity and fertility
- Adolescent PMOS diagnosis
- Long-term cardiometabolic risk in PMOS
- Mental health and quality of life
Pregnancy & postpartum
- Gestational diabetes mellitus
- Diabetes management during pregnancy
- Pregnancy-associated hypertension and pre-eclampsia
- Thyroid disorders in pregnancy
- Postpartum metabolic risk assessment
- Breastfeeding and maternal metabolic health
Menopause & beyond
- Metabolic health during menopause
- Dyslipidaemia and cardiovascular risk in women
- Thyroid disorders and metabolic interactions
- Osteoporosis and metabolic bone health
- Preventive healthcare and healthy ageing
- Sex differences in cardiometabolic disease
Clinical challenges we address
Under-diagnosis of PMOS
Many women wait years for a diagnosis, and metabolic risk is often overlooked.
Lost postpartum follow-up
Women with GDM frequently miss postpartum glucose testing.
Cardiovascular risk underestimated
Heart disease in women is under-recognised and under-treated.
Menopause transitions
Metabolic changes around menopause receive limited attention.
Siloed care
Gynaecology, endocrinology and cardiology are rarely coordinated.
Translating evidence into everyday care
IMACH promotes practical screening at key life stages and clear handovers between obstetric, gynaecological and metabolic care.
Life-stage pathway:
| Care stage | Focus for clinicians |
|---|---|
| Adolescence | Recognition of PMOS, weight and metabolic screening. |
| Reproductive years | Insulin resistance, fertility, pre-conception optimisation. |
| Pregnancy | GDM screening, blood-pressure monitoring, thyroid assessment. |
| Postpartum | Glucose testing, cardiovascular risk follow-up, lifestyle support. |
| Menopause & ageing | Lipids, bone density, body composition, cardiovascular prevention. |
IMACH programmes in this area
PMOS clinical update
Diagnosis, metabolic management and long-term follow-up.
GDM & pregnancy workshops
Screening, management and postpartum care.
Women’s heart health sessions
Recognising and treating cardiovascular risk in women.
Menopause & metabolism
Metabolic changes and preventive strategies.
Joint gynaecology–endocrinology forums
Shared-care discussions.
Who this area brings together
Women’s metabolic health needs collaboration across reproductive, metabolic and cardiovascular specialties.
Questions we explore
- How should metabolic screening be built into PMOS care?
- How can postpartum follow-up after GDM be improved?
- How should cardiovascular risk be assessed differently in women?
- What metabolic changes should be monitored around menopause?
Frequently asked questions
What is PMOS?
PMOS (polyendocrine metabolic ovarian syndrome) is the new name for the condition previously called polycystic ovary syndrome (PCOS). The new term reflects that it is a whole-body endocrine and metabolic condition, not only an ovarian one. IMACH uses PMOS throughout.
Is pregnancy care covered?
Yes — gestational diabetes, hypertension in pregnancy, thyroid disorders and postpartum follow-up.
Who leads this area?
IMACH’s panel includes gynaecology expertise; see the Experts page.
This page is intended for healthcare professionals and is educational in nature. It does not constitute medical advice or treatment recommendations for individual patients. Clinical decisions should follow current guidelines, local regulations and individual patient assessment.
Contribute to women’s metabolic care at IMACH.
Join as a member, faculty or research collaborator in this therapy area.